StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) stock

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30207% above fair value
$314.32−13.61 (-4.15%)

Close on Nov 20, 2026Market cap $15.01BP/E –Yield –

Charles River Laboratories International free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Charles River Laboratories International's free cash flow for the twelve months ending Jun 27, 2026 was $370.61M, down 35.9% year over year. For fiscal 2025 it was $518.49M, up 3.4% from the year before. Over ten years it grew 7.8% a year on average. The highest annual figure on record is $532.03M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 27, 2025$518.49M+3.4%
FY2024Dec 28, 2024$501.61M+37.3%
FY2023Dec 30, 2023$365.37M+23.9%
FY2022Dec 31, 2022$294.91M-44.6%
FY2021Dec 25, 2021$532.03M+40.0%
FY2020Dec 26, 2020$380.02M+11.6%
FY2019Dec 28, 2019$340.42M+13.1%
FY2018Dec 29, 2018$301.09M+27.8%
FY2017Dec 30, 2017$235.64M-9.9%
FY2016Dec 31, 2016$261.61M+7.4%
FY2015Dec 26, 2015$243.58M+24.8%
FY2014Dec 27, 2014$195.21M+14.9%
FY2013Dec 28, 2013$169.89M+5.9%
FY2012Dec 29, 2012$160.47M+1.8%
FY2011Dec 31, 2011$157.70M+25.8%
FY2010Dec 25, 2010$125.38M-7.6%
FY2009Dec 26, 2009$135.72M+76.4%
FY2008Dec 27, 2008$76.92M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$148.62M-12.2%
Q1 FY2026Mar 28, 2026-$14.83M-113.2%
Q4 FY2025Dec 27, 2025$58.57M-30.1%
Q3 FY2025Sep 27, 2025$178.25M-16.3%
Q2 FY2025Jun 28, 2025$169.31M+9.9%
Q1 FY2025Mar 29, 2025$112.37M+121.5%
Q4 FY2024Dec 28, 2024$83.75M-41.3%
Q3 FY2024Sep 28, 2024$213.07M+52.7%
Q2 FY2024Jun 29, 2024$154.05M+90.8%
Q1 FY2024Mar 30, 2024$50.74M+1923.3%
Q4 FY2023Dec 30, 2023$142.62M-2.1%
Q3 FY2023Sep 30, 2023$139.50M+131.0%
Q2 FY2023Jul 1, 2023$80.74M+21.2%
Q1 FY2023Apr 1, 2023$2.51M-88.7%
Q4 FY2022Dec 31, 2022$145.73M+11.7%
Q3 FY2022Sep 24, 2022$60.39M-49.3%
Q2 FY2022Jun 25, 2022$66.62M-52.5%
Q1 FY2022Mar 26, 2022$22.17M-84.4%
Q4 FY2021Dec 25, 2021$130.48M+158.3%
Q3 FY2021Sep 25, 2021$119.19M-21.1%
Q2 FY2021Jun 26, 2021$140.16M+3.4%
Q1 FY2021Mar 27, 2021$142.20M+231.7%
Q4 FY2020Dec 26, 2020$50.53M-56.8%
Q3 FY2020Sep 26, 2020$151.12M+25.2%
Q2 FY2020Jun 27, 2020$135.51M+29.3%
Q1 FY2020Mar 28, 2020$42.87M–
Q4 FY2019Dec 28, 2019$116.84M+63.9%
Q3 FY2019Sep 28, 2019$120.68M+27.3%
Q2 FY2019Jun 29, 2019$104.77M+2.1%
Q1 FY2019Mar 30, 2019-$1.87M-105.8%
Q4 FY2018Dec 29, 2018$71.30M-25.5%
Q3 FY2018Sep 29, 2018$94.81M+153.0%
Q2 FY2018Jun 30, 2018$102.66M+21.7%
Q1 FY2018Mar 31, 2018$32.33M+78.5%
Q4 FY2017Dec 30, 2017$95.73M+3.0%
Q3 FY2017Sep 30, 2017$37.47M-40.3%
Q2 FY2017Jul 1, 2017$84.33M–
Q1 FY2017Apr 1, 2017$18.11M–
Q4 FY2016Dec 31, 2016$92.97M–
Q3 FY2016Sep 24, 2016$62.73M–

More Charles River Laboratories International figures

See a number that looks wrong?